{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039871","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.872679+00:00","generated_at":"2026-06-12T03:25:47.437541+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Orthofix Q2 2023 revenue $187M (+7% pro forma), raises FY adjusted EBITDA guidance","bullets":["Net sales $187.0M, up 58% reported / 7% pro forma constant currency YoY.","GAAP EPS $(1.07); adjusted EPS $0.02; adjusted EBITDA $9.9M (5.3% margin).","Bone Growth Therapies grew 10.3% YoY; U.S. spine implants +7% pro forma.","FY23 net sales guidance raised to $752-758M; adjusted EBITDA to $42-46M.","Full commercial launch of WaveForm A interbody and TrueLok Phantom/Tornado hinges."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039871","json":"https://secwatch.observer/filing/0000950170-23-039871.json","markdown":"https://secwatch.observer/filing/0000950170-23-039871.md","text":"https://secwatch.observer/filing/0000950170-23-039871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000095017023039871/0000950170-23-039871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000095017023039871/ofix-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:25:47.437541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f664e9b259b36b9dc68a968c228cc5b6d039672b","claim":"Orthofix Medical Inc. reported the quarter ended June 30, 2023 results: revenue $187.0 million, EPS $(1.07). Guidance raised.","evidence_excerpt":"Legal judgments/sett --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Orthofix Reports Second Quarter 2023 Results and Raises Revenue and Adjusted EBITDA Guidance • Net sales of $187.0 million, an increase of 58% on a reported basis and 7% on a pro forma constant currency basis over prior year • Bone Growth Therapies growth of 10%, marking two consecutive quarters with","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017023039871/0000950170-23-039871-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$187.0 million"},{"label":"EPS","value":"$(1.07)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}